Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer

NCT05304936 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT05304936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 17, 2022
Completion date
February 15, 2025
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic carcinoma